• +1-646-491-9876
    • +91-20-67278686

    Search

    Human Cytomegalovirus Envelope Glycoprotein B-Pipeline Review H1 2017

    Human Cytomegalovirus Envelope Glycoprotein B-Pipeline Review H1 2017

    • Report Code ID: RW0001834443
    • Category Pharmaceuticals
    • No. of Pages 45
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2017

    Summary

    Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell.

    Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 1, 1 and 4 respectively. Report covers products from therapy areas Infectious Disease, Oncology and Women's Health which include indications Cytomegalovirus (HHV-5) Infections, Female Contraception, Glioblastoma Multiforme (GBM) , Gonorrhea, Human Immunodeficiency Virus (HIV) Infections (AIDS) , Medulloblastoma, Simplexvirus (HSV) Infections and Trichomonas Vaginitis.

    The latest report Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2017, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)
    - The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview
    Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development
    Astellas Pharma Inc
    Novartis AG
    Trellis Bioscience Inc
    Vakzine Projekt Management GmbH
    VBI Vaccines Inc
    Vical Inc
    Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles
    ASP-0113 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CSJ-148 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CyMVectin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PPCM - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TRL-345 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VBI-1501A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VBI-1901 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VPM-2001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products
    Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones
    Featured News & Press Releases
    May 02, 2017: VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study
    Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress
    Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
    Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate
    Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe
    Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients
    Sep 20, 2016: VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of its Preventative Cytomegalovirus Vaccine Candidate
    Sep 01, 2016: VBI Vaccines to Present at the Vaccine Congress
    Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit
    Aug 22, 2016: VBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review
    Jun 23, 2016: VBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate
    Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program
    Mar 29, 2016: VBI To Present At The World Vaccine Congress Washington
    Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference
    Nov 20, 2015: VBI Vaccines Presents Update and New Data Supporting its Glioblastoma Immunotherapy Program at the ESMO Symposium on Immuno-Oncology
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Astellas Pharma Inc, H1 2017
    Pipeline by Novartis AG, H1 2017
    Pipeline by Trellis Bioscience Inc, H1 2017
    Pipeline by Vakzine Projekt Management GmbH, H1 2017
    Pipeline by VBI Vaccines Inc, H1 2017
    Pipeline by Vical Inc, H1 2017
    Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Astellas Pharma Inc
    Novartis AG
    Trellis Bioscience Inc
    Vakzine Projekt Management GmbH
    VBI Vaccines Inc
    Vical Inc

    Request for Sample

    Report Url https://www.reportsweb.com//human-cytomegalovirus-envelope-glycoprotein-b-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//human-cytomegalovirus-envelope-glycoprotein-b-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//human-cytomegalovirus-envelope-glycoprotein-b-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments